What the End of a Tirzepatide Shortage Would Mean for Access to Compounded Weight Loss Drugs
In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its shortage list. Here's what taking the drug of the list could mean for people taking tirzepatide or its compounded versions.
FDA Says Compounding Pharmacies Can Keep Making Weight-Loss Med Tirzepatide, for Now
On October 7, a compounding trade group filed a lawsuit challenging the agency's action, saying there was still a shortage of the wildly popular drug.
FDA is reconsidering its decision to take tirzepatide off its drug shortage list
Pharmacists can continue making compounded versions of generic tirzepatide, the active ingredient in popular medications Mounjaro and Zepbound, the FDA said in a recent court filing.
FDA to reconsider decision barring sale of compounded Mounjaro: 5 things to know
The reconsideration follows an Oct. 11 lawsuit that prompted U.S. District Judge Mark Pittman to temporarily halt legal proceedings to give the FDA time to reassess its ruling.
Eli Lilly's tirzepatide is off the FDA's shortage list: What it means for patients
Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies say this will limit patient access.
Compounding pharmacies can resume making tirzepatide as FDA reconsiders shortage
The FDA said in a court filing late Friday that it would allow pharmacists to continue making compounded versions of tirzepatide as it reconsiders whether the drug is in shortage.
Should Eli Lilly Investors Worry About This Unexpected FDA Move?
Eli Lilly (NYSE: LLY) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven major gains in recent times. And that's the company's weight loss drugs. Lilly sells the compound tirzepatide under two different names -- Mounjaro for type 2 diabetes and Zepbound for weight loss.
FDA to Reconsider Removal of Lilly's Obesity Drug From Shortage List
The FDA has agreed to review its decision to remove Eli Lilly’s LLY tirzepatide — the active ingredient used in diabetes drug Mounjaro and obesity drug Zepbound — from its shortage list. During this process,
Mounjaro is more effective for weight loss than Ozempic—how does it work? And why does it cost so much?
A weight-loss drug more effective than Ozempic and Wegovy has recently been approved in Australia. The drug, tirzepatide, is ...
Mounjaro and Zepbound Are No Longer in Shortage, F.D.A. Says
The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...
FDA shakes up weight loss market as Mounjaro shortage ends
Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...
UK's weight loss jab Mounjaro might help people get back to work: All about it
The UK government starts a trial offering weight loss drug Mounjaro to unemployed obese individuals to improve health and ...
Mounjaro will soon be available as a weight loss treatment on the NHS – here’s what that means for patients
Now that Mounjaro has been authorised for use on the NHS, it will be key that access to specialist weight loss services is ...
The Hill13d
Mounjaro and Zepbound no longer in shortage
After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has ...
Everyday Health1d
Are Compounded Weight Loss Drugs on Their Way Out?
The FDA is weighing a decision that could stop compounding pharmacies from legally making cheaper versions of Mounjaro and ...
Tori Spelling’s Weight Loss of 40 lbs Using Mounjaro And Ozempic
Here are insights into Tori Spelling’s weight loss journey and how the actress toned herself down. From medications to diet ...
Wes Streeting’s jabs are no panacea – my own experience of Mounjaro was miserable
It was the insistent questioning of my four-year-old grandson that goaded me into it. “Why is your tummy so big” he asked ...